Unnikrishnan, R and Mohan, V (2021) Newer antidiabetic agents: at what price will they be cost effective? Lancet Diabetes and Endocrinology, 9 (12). pp. 801-803.
![]() | PDF Restricted to MDRF users only. Others may -> 146Kb |
Abstract
Type 2 diabetes is associated with substantial financial burden to patients and health-care systems around the world. Much of this burden is attributable to chronic complications of untreated diabetes, particularly those involving the cardiovascular system, kidneys, eyes, and feet. The situation is particularly critical in low-income and middle-income countries, where access to health insurance is limited, public health-care systems are suboptimal, and patients have to pay out-of-pocket for treatment of both diabetes and its complications.
Item Type: | Article |
---|---|
Official URL/DOI: | https://linkinghub.elsevier.com/retrieve/pii/S2213... |
Uncontrolled Keywords: | cost effective |
Subjects: | Diabetes |
Divisions: | Department of Diabetology |
ID Code: | 1374 |
Deposited By: | surendar radha |
Deposited On: | 29 Mar 2023 15:36 |
Last Modified: | 29 Mar 2023 15:36 |
Repository Staff Only: item control page